We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 1,683

Federal Circuit Rubberstamps 50-Year-Old Practice to Save 10,000 Continuation Patents
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing the question of precisely when a continuation application must be filed in order to be entitled to its parent application's filing date


No Rehearing on Dual Use PTAB Panels
  • McDermott Will & Emery
  • USA
  • July 26 2016

Confirming that the same panel of judges at the Patent Trial and Appeal Board (PTAB or Board) has the authority to institute America Invents Act


CBM Decisions Show Limits of Enfish
  • McDermott Will & Emery
  • USA
  • July 26 2016

Recent covered business method (CBM) review decisions by the Patent Trial and Appeal Board (PTAB or Board) demonstrate that the US Court of Appeals


In First Set of Post-Grant Review Decisions, PTAB Strikes Down Patents Based on Alice
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing for the first time the issue of patent validity in the context of an America Invents Act post-grant review, the Patent Trial and Appeal


Indirect Patent Infringement Can Be Based on Willful Blindness and Circumstantial Evidence
  • McDermott Will & Emery
  • USA
  • July 26 2016

In a case remanded by the Supreme Court of the United States "for further consideration in light of Commil" (IP Update, Vol. 18, No. 6), the US Court


Merck’s Damages Award for Infringement Thwarted by Gilead’s Equitable Defenses of Unclean Hands
  • McDermott Will & Emery
  • USA
  • July 19 2016

In this ongoing, multi-faceted case, the parties recently received the US District Court for the Northern District of California's rulings on whether


180-Day Notice Period for Biosimilar Approval Is Always Mandatory and Enforceable by Injunction
  • McDermott Will & Emery
  • USA
  • July 19 2016

A year after analyzing the patent dance and notice requirements of the Biologics Price Competition and Innovation Act (BPCIA) in Amgen Inc. v. Sandoz


District Court of New Jersey Boots Hospira’s Personal Jurisdiction and Rule 12(b)(6) Motions
  • McDermott Will & Emery
  • USA
  • July 19 2016

Relying on the US Court of Appeals for the Federal Circuit's recent decision in Acorda Therapeutics Inc. v. Mylan Pharmaceuticals, Inc., Nos. 15-1456


Federal Circuit Rejects Argument that Claim Is Novel because Composition Exhibits ‘Pharmaceutically Effective Absorption’
  • McDermott Will & Emery
  • USA
  • July 19 2016

Where a claim was distinguished from the prior art only because it contained a limitation requiring "pharmaceutically effective absorption," the US


New Jersey Court Grants Motion to Dismiss by Patentee Drug Maker, Further Defining an Officially Received ANDA
  • McDermott Will & Emery
  • USA
  • July 19 2016

Granting a motion to dismiss, US District Court for the District of New Jersey held that the statutory act of patent infringement no longer exists